Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ceftazidime-avibactam

ceftazidime-avibactam

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ceftazidime-avibactam

8 trials tracked of ceftazidime-avibactam: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 101 citations.

8Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 1 Phase 3 1 Phase 2 3 Phase 1 1 Other / NA 2
  1. Phase 3 Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections Completed · 101 cited
  2. Phase 4 Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis Completed · 49 cited
  3. Phase 2 Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs). Completed
  4. Phase 2 A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam Completed
  5. Phase 2 Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs) Completed
  6. Phase 1 A Study of Avycaz (Ceftazidime/Avibactam) Pharmacokinetics/Pharmacodynamics (PK/PD) in Critically Ill Patients Completed
Show 2 more trials
  1. N/A Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving CVVHDF Completed
  2. N/A Retrospective Analysis of Real World Use of Ceftazidime-avibactam in the Management of Gram Negative Infections Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Ceftolozane-tazobactam associated with higher clinical cure rates in multidrug-resistant Pseudomonas aeruginosa infections
Infectious Disease Meta-analysis
Ceftolozane-tazobactam associated with higher clinical cure rates in multidrug-resistant Pseudomonas aeruginosa infections Comparing Two Different Antibiotics for Treating Tough Pseudomonas Aeruginosa Infections
Researchers compared ceftolozane-tazobactam and ceftazidime-avibactam for treating multidrug-resistant and difficult-to-treat Pseudomonas ae…
Doctors are comparing two powerful antibiotics to see which one works best against hard-to-treat bacterial infections.
Sep 11, 2026
Pharmacokinetic and clinical data inform therapeutic selection for difficult to treat Pseudomonas aeruginosa CNS infections
Allergy & Immunology Sys. Review
Pharmacokinetic and clinical data inform therapeutic selection for difficult to treat Pseudomonas aeruginosa CNS infections New strategies help treat drug resistant brain infections
This narrative review evaluates the feasibility of various antimicrobial agents, including ceftolozane-tazobactam, ceftazidime-avibactam, az…
Doctors are finding new ways to treat serious brain infections caused by bacteria that have become hard to kill with standard medicine.
Frontiers Aug 4, 2026
Ceftolozane-tazobactam shows comparable efficacy to ceftazidime-avibactam but lower risk of recurrent infection
Infectious Disease Meta-analysis
Ceftolozane-tazobactam shows comparable efficacy to ceftazidime-avibactam but lower risk of recurrent infection New analysis shows lower risk of repeat infections for patients
This systematic review and meta-analysis of 3,361 patients with drug-resistant Pseudomonas aeruginosa infections found no significant differ…
A new review of 3,361 patients found that one specific antibiotic may help prevent recurring infections in those with drug-resistant bacteri…
Aug 3, 2026
Meta-analysis shows carbapenems linked to higher clinical failure in OXA-48-PE infections
Infectious Disease Meta-analysis
Meta-analysis shows carbapenems linked to higher clinical failure in OXA-48-PE infections Doctors found higher death rates when using carbapenems for certain gut bacteria infections
This meta-analysis and review synthesizes data on carbapenem therapy for monomicrobial OXA-48-producing Enterobacterales infections. The aut…
A large review of patients with OXA-48 bacteria showed that carbapenem drugs often failed to work. Newer medicines offered better survival c…
May 24, 2026
Review of Therapeutic Options for Carbapenem-Resistant Enterobacterales
Drug Pipeline RCT
Review of Therapeutic Options for Carbapenem-Resistant Enterobacterales New Weapons Emerge in the Fight Against Deadly Superbugs
This review summarizes available and emerging therapies for carbapenem-resistant Enterobacterales.
New drug combinations offer hope for patients facing deadly superbugs that resist almost all current antibiotics.
Frontiers Apr 18, 2026
Meta-analysis finds no mortality difference between CA and CT for drug-resistant P. aeruginosa infections
Infectious Disease Meta-analysis
Meta-analysis finds no mortality difference between CA and CT for drug-resistant P. aeruginosa infections Which antibiotic works better for dangerous drug-resistant infections?
A meta-analysis of 10 observational studies including 1409 patients with drug-resistant P.
Two powerful new antibiotics show equal survival rates for patients fighting dangerous, drug-resistant infections.
Apr 2, 2026